2.92

7.59% -0.24

Pre-market: 2.90 -0.02 -0.68%

Sana Biotechnology Inc (SANA)

Overview News Price History Option Chain Financials Why SANA Down? Discussions Forecast

Sana Biotechnology Inc stock is traded at $2.92, with a volume of 6.78M. It is down -7.59% in the last 24 hours and up +76.97% over the past month. Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.

Previous Close:

$3.16

Open:

$3.17

24h Volume:

6.78M

Relative Volume:

1.24

Market Cap:

$651.95M

Revenue:

Net Income/Loss:

$-283.26M

P/E Ratio:

-1.9864

EPS:

-1.47

Net Cash Flow:

$-273.61M

1W Performance:

-19.56%

1M Performance:

+76.97%

6M Performance:

-49.66%

1Y Performance:

-42.29%

1-Day Range:

$2.90

$3.275

1-Week Range:

$2.90

$3.86

52-Week Range:

$1.52

$12.00

Sana Biotechnology Inc Stock (SANA) Company Profile

Name

Sana Biotechnology Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

(206) 701-7914

Address

188 EAST BLAINE STREET, SUITE 400, SEATTLE

Employee

328

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

SANA's Discussions on Twitter

Compare SANA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SANA Sana Biotechnology Inc	2.92	651.95M	0	-283.26M	-273.61M	-1.47
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Nov-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-26-24	Initiated	Rodman & Renshaw	Buy
Jan-16-24	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-25-23	Initiated	JMP Securities	Mkt Outperform
Sep-05-23	Initiated	Citigroup	Buy
Aug-14-23	Initiated	TD Cowen	Market Perform
May-02-23	Initiated	H.C. Wainwright	Neutral
Mar-01-21	Initiated	BofA Securities	Buy
Mar-01-21	Initiated	Goldman	Neutral
Mar-01-21	Initiated	JP Morgan	Neutral
Mar-01-21	Initiated	Morgan Stanley	Overweight

View All

Sana Biotechnology Inc Stock (SANA) Latest News

Jan 20, 2025

Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace

Jan 17, 2025

Jan 16, 2025

As researchers push for a type 1 diabetes cure, Sana Biotechnology provides a nudge forward - STAT

Jan 16, 2025

Jan 15, 2025

Sana Biotechnology (NASDAQ:SANA) Shares Down 5.5%Here's What Happened - MarketBeat

Jan 15, 2025

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 5.7%Here's Why - MarketBeat

Jan 15, 2025

Jan 14, 2025

Sana Biotechnology price target raised to $12 from $9 at Morgan Stanley - MSN

Jan 14, 2025

Jan 13, 2025

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data - MSN

Jan 13, 2025

Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7%Time to Buy? - MarketBeat

Jan 13, 2025

This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025. - MSN

Jan 13, 2025